However, the expression of lymphocyte-activation gene 3 (LAG-3) protein was also distinctly higher in CD8+ T cells, specifically in the tumor-associated communities, in which ~30% of PD-1+ T cells were also LAG3+ following treatment with MRTX1257. This evidence concerns the gene LAG3 and neoplasm.